Skip to main content
Premium Trial:

Request an Annual Quote

ProteoMetrics, Base4


ProteoMetrics of New York has released new high-throughput software for protein identification, called Radars Knexus. The product is a simplified interface for analyzing and storing results from medium-scale proteomics experiments.

Radars Knexus combines the company’s ProFound search engine with its Radars proteomic data analysis system to simplify the process of analyzing batches of mass spectral data, said ProteoMetrics. Protein sequence databases are searched with the Radars algorithms using information from mass spectral peptide maps generated by mass spectrometers.

The integration of these programs enables automated data retrieval and comparative analysis.

Base4 of Toronto has released Alerts! 2.0 and has begun development of its Timesheet module. Alerts provides a link for scientists to capture and share findings, automate search and review processes, and notify teams about new developments. The product also has an email component that enables access to the PharMatrix central repository without having to be logged on. PharMatrix is the company’s core bioinformatics product. In addition, the Alerts External Services component allows Internet tools and external processes, such as scientific search engines, to be used.

Filed under

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.